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Abstract: The emergence of multi-drug-resistant bacteria, coupled with the lack of new
antibiotics in development, is fast evolving into a global crisis. New strategies utilizing
existing antibacterial agents are urgently needed. We propose one such strategy in which
four outmoded β-lactam antibiotics (ampicillin, carbenicillin, cephalothin and oxacillin) and
a well-known antiseptic (chlorhexidine di-acetate) were fashioned into a group of uniform
materials based on organic salts (GUMBOS) as an alternative to conventional combination
drug dosing strategies. The antibacterial activity of precursor ions (e.g., chlorhexidine
diacetate and β-lactam antibiotics), GUMBOS and their unreacted mixtures were studied
with 25 clinical isolates with varying antibiotic resistance using a micro-broth dilution
method. Acute cytotoxicity and therapeutic indices were determined using fibroblasts,
endothelial and cervical cell lines. Intestinal permeability was predicted using a parallel
artificial membrane permeability assay. GUMBOS formed from ineffective β-lactam
antibiotics and cytotoxic chlorhexidine diacetate exhibited unique pharmacological
properties and profound antibacterial activity at lower concentrations than the unreacted
mixture of precursor ions at equivalent stoichiometry. Reduced cytotoxicity to invasive cell
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types commonly found in superficial and chronic wounds was also observed using
GUMBOS. GUMBOS show promise as an alternative combination drug strategy for treating
wound infections caused by drug-resistant bacteria.
Keywords: chlorhexidine; β-lactam antibiotic; multi-drug resistant; GUMBOS; combination
drug therapy; ion pair; antibacterial; synergy

1. Introduction
Ineffective antibiotics are a pervasive reality that has contributed to higher incidences of infectious
diseases caused by multi-drug-resistant bacteria, namely “ESKAPE” pathogens (i.e., Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa and Enterobacter species) [1]. The nonexistent antibiotic pipeline and perceived lack of
political interest towards drug-resistant bacteria have worsened the fight against drug-resistant infections
and has initiated a post-antibiotic era [2]. Thus, last resort treatment, particularly for drug-resistant
superficial and chronic wound management, relies heavily on prompt and appropriate antimicrobial
therapy for the delivery of improved clinical prognoses [3].
Drug-resistant bacteria represent an area of increasing concern in wound infections. Wound
colonization with multi-drug-resistant bacteria requires aggressive treatment with the limited arsenal
of effective, therapeutic antibiotics. Recent interest in counteracting drug-resistant wound infections
has led to administering antibiotics simultaneously for treatment [3]. Combination drug therapy has
contributed to some clinical and commercial successes against many vectors of human disease [4–6].
In particular, antibiotic combinations have been used to: (1) improve the efficacy of treatment; (2) reduce
dosing concentrations; (3) extend treatment response; (4) expand pharmaceutical use of an approved
drug; and (5) minimize the rate at which microbes acquire resistance [5]. In the last decade, however,
research interest in antibiotic combinations has grown from the conventional use of two antibiotics to
substituting one antibiotic with an unconventional over-the-counter consumer drug or prescription-only
non-antibiotic drug. Examples of these efforts have expanded to include barbiturates, antipsychotics,
antivirals and analgesics to improve the efficacy of antibiotic treatment [7–13]. Yet, these approaches
are still in their infancy, and despite improved activity against some drug-resistant bacteria, some
challenges still remain before clinical use is possible.
Many clinical research reports detail the difficulty in translating in vitro combination antibiotic
results acquired at the bench into positive patient outcomes [14–16]. This is partly attributed to
fluctuating pharmacokinetic properties and narrow therapeutic indices [17,18]. Conventional antibiotic
combinations have not completely addressed the challenge of treating infections caused by
multi-drug-resistant bacteria, especially when incremental and ineffective antibiotic dosing strategies
are employed that do not overcome individual mechanisms of resistance [19]. From these studies, it has
become apparent that effective therapy not only lies in the judicious choice of agent, but also in the
ability to control the delivery and concentration of drugs used in combination [20]. Therefore, effective
combination antibiotic therapy is highly dependent on dosing strategies that contain both
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pharmacophores as one entity, have favorable pharmacokinetics, low toxicity and antimicrobial activity
against multi-drug-resistant bacteria.
The literature supports the use of GUMBOS (group of uniform materials based on organic salts) as a
chemical approach that could remedy some challenges posed by conventional drug combination
therapy [21–24]. GUMBOS are a new series of hybrid materials composed of at least two functional
organic and/or inorganic counter-ions and melt between 25 °C and 250 °C. Previous approaches using
low-melting salts, like ionic liquids, have focused more on the desirable physical properties rather than
enhancing the active properties and functional uses of the ion pair. However, the limited number of
counter-ions that produce nontoxic and functional ionic liquids (Mp <100 °C) makes this approach
appear to be a challenging art form instead of a science [25–28]. Since most ion pairs melt below
250 °C, GUMBOS permit the pairing of any charged pharmaceutical species to obtain tailor-made
hydrophobic ion pairs with favorable physical, toxicity, pharmacokinetic and pharmacophoric properties
through simple chemical reactions [29–31]. GUMBOS represent an avenue that allows charged
non-antibiotics and/or antibiotics to be explored inclusively as an adjuvant therapy composed of one
molecule, rather than a mixture of unreacted molecules, as done in conventional combination drug
therapy [24]. Options for therapy can also be expanded to include outmoded antibiotics, non-antibiotics
with membrane altering and potential antibacterial features and mixed-modal systems to facilitate
superficial and chronic wound management [27,28,32,33].
Herein, the in vitro antimicrobial efficacy and synergistic activities of β-lactam-based chlorhexidine
GUMBOS (Figure 1) synthesized from outmoded β-lactam antibiotics and the toxic antiseptic,
chlorhexidine, against 25 clinical isolates (Table 1) are shown. Comparative analyses between
GUMBOS and conventional combination drug studies further confirm the potential of this approach for
innovative antimicrobial therapeutic strategies. The toxicities of the GUMBOS were also evaluated with
three different cell lines representative of superficial and chronic wound beds.

Figure 1. Structures of precursor ions and β-lactam-based chlorhexidine GUMBOS [24].
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Table 1. Drug-susceptible and drug-resistant bacterial strains.

Strain
Escherichia coli 29522 +
Escherichia coli O157:H7 43895 +
Salmonella typhi ++
Acinetobacter baumannii 225T2 ++
Acinetobacter baumannii 250 ++
Acinetobacter baumannii 252 ++
Acinetobacter baumannii 254 ++
Enterobacter cloacae 210T2 ++
Enterobacter aerogenes 221T2 ++
Klebsiella pneumoniae 10031 +
Klebsiella pneumoniae 50T2 ++
Klebsiella pneumoniae 86T2 ++

Abbreviation
EC 29522
EC 43895
Styphi
AB 225T2
AB 250
AB 252
AB 254
EC 210T2
EA 221T2
KP 10031
KP 50T2
KP 86T2

Pseudomonas aeruginosa 124T2 ++

PA 124T2

Pseudomonas aeruginosa 27853 +
Pseudomonas aeruginosa PSA3 ++

PA 27853
PSA 3

Pseudomonas aeruginosa PSA4 ++

PSA 4

Serratia marcescens ++
Staphylococcus aureus 25923 +
Streptococcus mutans35668 +
Streptococcus faecalis 19433 +
Micrococcus luteus 4698 +
Streptococcus faecalis 9790 +
Bacillus cereus 1178 +
Methicillin-resistant
Staphylococcus aureus
Methicillin-resistant ++CA-MRSA 2
Staphylococcus aureus ++ CA-MRSA 1

SM
SA 25923
SM 35668
SF 19433
ML 4698
SF 9790
BC 1178

Characteristic
Clinical isolate, quality control organism
EHEC, hamburger isolate (stx1+, stx2+)
Fluoroquinolone resistant
Respiratory isolate, multi-drug resistant *
Skin isolate, multi-drug resistant
Catheter isolate, multi-drug resistant
Wound drain isolate, multi-drug resistant
Pleural fluid isolate, multi-drug resistant
Sputum, multi-drug resistant
Quality control organism
Urine isolate, multi-drug resistant
Pleural fluid isolate, multi-drug resistant
Respiratory: sputum isolate, β-lactam
drug resistant
Blood isolate, quality control organism
Urine Isolate, β-lactam drug resistant
Sputum isolate, β-lactam, fluoroquinolone,
carbapenem drug resistant
Wound isolate, multi-drug resistant
Clinical isolate
Quality control organism
Quality control organism
Quality control organism
Quality control organism
Quality control organism

CA-MRSA 2

Wound isolate, vancomycin susceptible

CA-MRSA 1

Prosthetic joint infection isolate,
vancomycin susceptible

* Multi-drug resistant = β-lactam, fluoroquinolone, carbapenem, aminoglycoside resistant; + obtained from
American Type Culture Collection, Manassas, VA; ++ obtained from Jeffrey A. Hobden, Louisiana State
University Health Science Center, LA.

2. Results and Discussion
2.1. Aqueous Solubility, Dissolution and Theoretical Intestinal Absorption
First order dissolution rates were found for GUMBOS after replacing the acetate anion with the
β-lactam antibiotic (Table 2). Dissolution rates among the chlorhexidine-based GUMBOS decreased in
this order (by antibiotic): oxacillin ≥ ampicillin > cephalothin > carbenicillin; which was found to
parallel the order of aqueous solubility of GUMBOS. Reduced solubility as observed for GUMBOS is
attributable to greater lipophilicity and increased intermolecular interactions. The reduced aqueous
solubility of GUMBOS is directly related to their potential to be more bioavailable. In fact, exchanging
the acetate anion with an antibiotic significantly improved estimated intestinal permeability for the
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GUMBOS (p < 0.05). Mean effective permeability coefficients for the GUMBOS were 9.39 × 10−7
(±0.87), 4.03 × 10−6 (±1.03), 3.67 × 10−6 (±0.74), 4.98 × 10−6 (±0.087) and 4.91 × 10−6 (±0.17) cm/s
for chlorhexidine diacetate, chlorhexidine di-ampicillin, chlorhexidine carbenicillin, chlorhexidine
di-cephalothin and chlorhexidine di-oxacillin, respectively. Predicted permeability increased four times
when chlorhexidine diacetate was converted into a β-lactam-based chlorhexidine GUMBOS. No
significant differences were found among permeability coefficients for GUMBOS (p < 0.05).
This observation suggests that there is a greater chemical difference between the GUMBOS and
chlorhexidine diacetate than there is amongst each other, and thus, they may behave as a new ion pair
when used therapeutically.
Table 2. Summary of aqueous solubility, pharmacokinetic properties and intestinal
bioavailability for β-lactam-based chlorhexidine GUMBOS.
Antimicrobial
Agent a
CHX Ac
CHX Amp
CHX Carb
CHX Ceph
CHX Oxa

Solubility,
mg/mL
10
0.126
0.055
0.079
0.166

Dissolution Rate
(k), min−1
na b
0.0188
0.0022
0.0037
0.0189

Permeability
Coefficients, cm/s (SD)

Log Permeability
Coefficients

% HIA c

9.39 × 10−7 (±0.87)
4.03 × 10−6 (±1.03)
3.67 × 10−6 (±0.074)
4.98 × 10−6 (±0.082)
4.91 × 10−6 (±0.17)

−6.10
−5.39
−5.43
−5.30
−5.31

77.4
101.9
100.4
105.5
105.3

a

CHX Ac: chlorhexidine diacetate; CHX Amp: chlorhexidine di-ampicillin; CHX Ceph: chlorhexidine
di-cephalothin; CHX Oxa: chlorhexidine di-oxacillin; b na: not applicable; c %HIA: the percent theoretical
human intestinal absorption of the drug as determined from the PAMPA permeability assay.

Since simple hydrophobic ion pairing systems have yet to be completely understood, describing the
aqueous dissolution of the GUMBOS is not a trivial task. However, what is known to date is that the
strength of electrostatic interaction shows little dependence on the size of the ions involved [34].
In general, the dissolution of a salt is not only dependent on differences in stabilities of the ions in water,
their hydrophobicity and the energy required to hydrate them, but also on overcoming the energies of
other intermolecular forces between these ions. The water-soluble acetate anion in chlorhexidine
diacetate has a high charge density and subsequently a large hydration sheath that surrounds each anion.
Therefore, less hydration energy is needed to dissolve chlorhexidine diacetate as compared to the anions
in the less soluble antibiotic-antiseptic ion pair (e.g., β-lactam-based chlorhexidine GUMBOS). This is
because large and/or more hydrophobic ion pairs have stronger electrostatic bonds, despite their
asymmetrical lattice and smaller charge densities that limit their interactions with the surrounding
aqueous medium and, thus, their aqueous dissociation [34,35]. Lengsfeld et al. (2002) classified
hydrophobic ion pairs that exhibited such behavior as units that form intermediate tight or loose pairs
rather than salts that completely dissolve into individual ions [32,34,35]. This is especially evident for
the GUMBOS when comparing two structurally similar anions (i.e., ampicillin and carbenicillin), where
it was found that chlorhexidine di-ampicillin (symmetrical, two anions) behaved more as a loose ion pair
with a higher dissolution rate (~9×) and greater aqueous solubility (~2×) than chlorhexidine carbenicillin
(asymmetrical, one anion and tight pair). The marked differences in solubility and intestinal permeability
values between chlorhexidine diacetate and GUMBOS support the contention that the GUMBOS ions
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are travelling as one molecule and not as mixed, separate ions. This outcome is further supported by the
antibacterial results.
2.2. Antibacterial Activities of β-Lactam-Based Chlorhexidine GUMBOS
The antibacterial activity of the precursor components to the GUMBOS were assessed against each
parent ion individually and as a stoichiometrically equivalent mixture (Tables 3–5). Initial antibacterial
studies with β-lactam antibiotics and chlorhexidine diacetate were found most effective against
drug-susceptible bacteria, in which the β-lactam antibiotics were preferential toward Gram-positive
bacteria (Gram-positive bacteria) and within acceptable MIC ranges and chlorhexidine diacetate against
Gram-negative bacteria (GNB) (Tables 3 and 4). As expected, extremely high concentrations of β-lactam
antibiotic were required to inhibit the growth of the multi-drug-resistant isolates and required
concentrations greater than 1250 µM for growth inhibition.
Table 3. MICs (μM) of β-lactam antibiotics, chlorhexidine diacetate and four GUMBOS
against 8 clinical isolates of Gram-positive bacteria with β-lactam antibiotic resistance a.
Gram-Positive
Bacteria
SA 25923
SM 35668
SF 19433
ML 4698
SF 9790
BC 1178
CA-MRSA 2
CA-MRSA 1
a

Amp

Carb

2
0.8
0.2
625
625
625
625
>1250

13
94
0.1
>1250
>1250
>1250
>1250
>1250

Antibacterial Agent b
CHX
Ceph
Oxa
Ac
125
125
1
104
98
0.4
0.1
0.1
0.8
>1250
>1250
0.8
>1250
>1250
0.8
>1250
>1250
0.4
>1250
>1250
1
>1250
>1250
0.7

CHX
Amp
0.9
0.4
0.4
0.6
0.8
0.4
0.8
0.7

CHX
Carb
0.5
0.4
0.8
0.5
0.8
0.4
0.7
0.3

CHX
Ceph
0.4
0.4
0.8
0.3
0.8
0.4
0.4
0.3

CHX
Oxa
0.5
0.4
0.4
0.1
0.8
0.2
0.2
0.2

The maximum concentration tested was 1250 μM; b Amp: sodium ampicillin; Carb: carbenicillin disodium,
Ceph: sodium cephalothin; Oxa: sodium oxacillin; CHX Ac: chlorhexidine diacetate; CHX Amp:
chlorhexidine di-ampicillin; CHX Carb: chlorhexidine carbenicillin; CHX Ceph: chlorhexidine di-cephalothin;
CHX Oxa: chlorhexidine di-oxacillin.
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Table 4. MICs (μM) of β-lactam antibiotics, chlorhexidine diacetate and four GUMBOS against 17 clinical isolates of Gram-negative bacteria
of varying antibiotic resistance a.
Gram-Negative Bacteria
EC 29522
EC 43895
Styphi
AB 225T2
AB 250
AB 252
AB 254
EC 210T2
EA 221T2
KP 10031
KP 50T2
KP 86T2
PA 124T2
PA 27853
PSA 3
PSA 4
SM
a

Amp
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
27
540
14
10
28
32
>1250
>1250

Carb
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
22
270
28
10
28
39
>1250
>1250

Ceph
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
>1250
29
270
28
10
28
27
>1250
>1250

Antibacterial Agent b
Oxa
CHX Ac
>1250
0.3
>1250
0.2
>1250
0.2
>1250
12
>1250
20
>1250
29
>1250
4
>1250
15
>1250
16
17
5
215
5
28
6
5
22
28
6
45
4
>1250
6
>1250
9

CHX Amp
0.3
0.1
0.2
12
24
20
4
20
24
13
12
7
10
8
12
20
22

CHX Carb
0.2
0.1
0.1
15
7
20
10
24
20
13
20
10
15
8
15
20
22

CHX Ceph
0.2
0.1
0.1
20
7
20
7
24
20
13
20
20
10
3
10
15
32

CHX Oxa
0.2
0.1
0.1
15
7
20
10
10
10
13
10
10
15
3
10
10
16

The maximum concentration tested was 1250 μM; b Amp: sodium ampicillin; Carb: carbenicillin disodium, Ceph: sodium cephalothin; Oxa: sodium oxacillin; CHX Ac:
chlorhexidine diacetate; CHX Amp: chlorhexidine di-ampicillin; CHX Carb: chlorhexidine carbenicillin; CHX Ceph: chlorhexidine di-cephalothin; CHX Oxa:
chlorhexidine di-oxacillin.
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Table 5. MICs (μM) and FICI of four GUMBOS and their unreacted mixtures at stoichiometric equivalence against three quality control strains a.
SA 25923
MIC
FICI b
Effect
KP 10031
MIC
FICI
Effect
PA 27853
MIC
FICI
Effect
a

CHX Amp

1 CHX:2 Amp

CHX Carb

1 CHX:1 Carb

CHX Ceph

1 CHX:2 Ceph

CHX Oxa

1 CHX:2 Oxa

0.9
0.3
syn

2.4
0.2
syn

0.5
0.3
syn

18.8
7.1
ant

0.4
0.1
syn

9.4
3.4
add

0.5
0.2
syn

2.0
1.3
add

12.5
0.9
add

37.5
2.7
add

12.5
1.3
add

37.5
2.7
add

12.5
0.9
add

18.8
1.5
add

12.5
0.9
add

18.8
2.0
add

7.8
0.4
syn

18.8
1.3
add

7.8
0.6
add

18.8
1.5
add

3.1
0.2
syn

9.4
0.8
add

3.1
0.2
syn

18.8
1.5
add

1 CHX: 2 Amp: 1 mole chlorhexidine diacetate: 2 moles sodium ampicillin; CHX Amp: chlorhexidine di-ampicillin; 1 CHX: 1 Carb: 1 mole chlorhexidine diacetate:
1 mole disodium carbenicillin; CHX Carb: chlorhexidine carbenicillin; 1 CHX: 2 Ceph: 1 mole chlorhexidine diacetate: 2 moles sodium cephalothin; CHX Ceph:
chlorhexidine di-cephalothin; 1 CHX: 2 Oxa: 1 mole chlorhexidine diacetate: 2 moles sodium oxacillin; CHX Oxa: chlorhexidine di-oxacillin; b Fractional Inhibitory
Concentration Interaction Index (FICI) ≤ 0.5, synergy (syn); 0.5 < FICI ≤ 3, additivity (add); FICI > 3, antagonism (ant).
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Antibacterial activity against Gram-positive bacteria, including MRSA, are listed in Table 3.
GUMBOS inhibited drug-susceptible Gram-positive bacteria including MRSA with <0.7 µM
(0.56 µg/mL). Lower concentrations of GUMBOS were required to inhibit the growth of Gram-positive
bacteria and MRSA than that found for chlorhexidine diacetate. On average, GUMBOS required
approximately half the moles than chlorhexidine diacetate to inhibit Gram-positive bacteria. However,
GUMBOS needed 25, 40, 2444, and 3400×fewer moles than β-lactam antibiotics to inhibit Micrococcus
luteus (ML) 4698, SA 25,923 and both MRSA isolates, CA-MRSA 2 and CA-MRSA 1, respectively.
Consequently, antibacterial activity was improved in the chlorhexidine ion pair after the acetate was
exchanged for the antibiotic, which increased similarly with known antibiotic efficacy against
Gram-positive bacteria: acetate < ampicillin ≤ carbenicillin < cephalothin < oxacillin. Comparable
results for Gram-positive bacteria, including MRSA, to the chlorhexidine ion-pairs suggest that synergy
may exist between the chlorhexidine and antibiotics when used as GUMBOS. This result is in spite of
the β-lactam resistance of the MRSA strains. Thus, GUMBOS’s superior activity is attributable to the
bulky nature of the chlorhexidine cation that may have sterically hindered β-lactamase attachment and/or
deactivation of the antibiotic pharmacophore in the MRSA strains. Future studies are underway to
evaluate β-lactamase activities in the presence of these GUMBOS, as this method may impart a new
treatment approach for resistant infections in which enzymes are used in antibiotic deactivation mechanisms.
Antibacterial activities upon GNB are illustrated in Table 4. GUMBOS concentrations to inhibit
drug-susceptible GNB followed a similar trend as that observed with Gram-positive bacteria and
required nearly half the concentration of chlorhexidine diacetate. Significant improvements (i.e.,
300–710×) in antibacterial activity were mostly seen for EC 29522 and EC 43895 isolates when
comparing β-lactam antibiotics and GUMBOS (p < 0.05). These findings agree with previous reports by
Cole et al. (2013) [24]. There was no significant difference in mean antibacterial activities between
β-lactams and GUMBOS against S. typhi (p < 0.05).
Antibacterial activity was species-dependent for the multi-drug-resistant Gram-negative bacteria
tested (Table 4). Overall, GUMBOS inhibited the growth of multi-drug-resistant Gram-negative bacteria
in this order: S. marcescens < K. pneumoniae < E. cloacae < P. aeruginosa < A. baumannii; in which
the least antibacterial activity was observed on S. marcescens. In comparing the individual activity of
each GUMBOS, it was found that specific β-lactam-based chlorhexidine ion pairs (GUMBOS) were
more effective towards certain genera of multi-drug-resistant Gram-negative bacteria. For instance,
chlorhexidine di-ampicillin outperformed other GUMBOS when inhibiting A. baumannii. Comparable
inhibition of P. aeruginosa was observed for all GUMBOS and chlorhexidine diacetate. Chlorhexidine
di-oxacillin was twice more effective towards E. cloacae than the other GUMBOS and chlorhexidine
diacetate. GUMBOS preferentially inhibited neither K. pneumoniae nor S. marcescens and required a
2–4× greater concentration than chlorhexidine diacetate for similar activity. Exchanging acetate in
chlorhexidine salts for a β-lactam antibiotic yielded superior antibacterial activity against 57% of
multi-drug-resistant Gram-negative bacteria isolates evaluated in this study. Mean concentrations
required to inhibit drug-susceptible GNB and multi-drug-resistant Gram-negative bacteria were
0.1 ±0.06 µM and 14 ±6 µM, respectively. Overall, GUMBOS inhibited 88% of the multi-drug-resistant
Gram-negative bacteria tested with less than 20 µM (23.5 µg/mL), and 45% of that population was
inhibited under 10 µM (11.7 µg/mL).
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Examination of several literature reports suggests that extraneous anions impair the antibacterial
activity of chlorhexidine salts [36,37]. Since such issues can limit some combination drug studies and
the use of outmoded antibiotics (or other previously approved non-antibiotics) in the form of GUMBOS,
the combined interactions of chlorhexidine diacetate and various β-lactam antibiotics at appropriate,
equal stoichiometry were evaluated to determine if this applies to GUMBOS or if it is exclusive to their
unreacted mixtures. The antibacterial efficacy of GUMBOS and unreacted mixtures against S. aureus
29523, K. pneumoniae 10031 and P. aeruginosa 27853 are listed in Table 5.
2.3. Comparison of Antibacterial Activity between Reacted β-Lactam-Based Chlorhexidine GUMBOS
and Its Unreacted Mixtures
Table 5 lists the antibacterial activity of the reacted GUMBOS and unreacted mixture of chlorhexidine
diacetate and β-lactam antibiotic. Mixtures of chlorhexidine diacetate and β-lactam antibiotic were most
effective on S. aureus 29523 and increased (by antibiotic) in this order: ampicillin  carbenicillin (2 μM)
< cephalothin (9 μM) < oxacillin (19 μM). This trend is opposite to the strength of the antibiotics when
used alone and at 3–11× less concentration (p < 0.05). However, neither mixture used fewer moles to
inhibit S. aureus 29523 than chlorhexidine diacetate nor was more effective than their respective
GUMBOS. Interaction indices determined by MIC values against S. aureus 29523 support that synergy
(Fractional Inhibitory Concentration Interaction Index, FICI <0.5) occurred exclusively as a GUMBOS
rather than the combined, unreacted mixture of chlorhexidine diacetate and sodium antibiotic. Higher
interaction indices (FICI >3) suggest that antagonism was evident when chlorhexidine diacetate was
mixed with β-lactam antibiotics, although both individually were effective in inhibiting S. aureus 29523.
Regardless of being the most effective antibiotic towards S. aureus 29523, antagonism was greatest when
sodium oxacillin was mixed with chlorhexidine diacetate. Synergetic mixtures with less antagonism
decreased with increasing β-lactam strength, hydrophobicity and size. This result corroborates previous
findings regarding extraneous ions interfering with the antibacterial activity of chlorhexidine salts. Thus,
GUMBOS are truly interacting with bacteria as one entity and not as two separate antimicrobials.
Since K. pneumoniae 10031 and P. aeruginosa 27853 are clinically resistant to many antibiotics,
including the β-lactam class, it was expected that worse antibacterial activity would be observed as
compared to that found for S. aureus 29523. In each instance, the GUMBOS were more effective than
the unreacted mixture of precursor ions. For these microrganisms, the more hydrophobic antibiotics
(i.e., sodium cephalothin and sodium oxacillin) combined with chlorhexidine diacetate resulted in better
FICI values than that observed with S. aureus 29523. All interactions between chlorhexidine diacetate
and sodium antibiotic were additive when inhibiting K. pneumoniae 10031. Likewise, GUMBOS were
found to have an additive interaction index (0.5 < FICI < 3). Thus, neither chlorhexidine diacetate nor
β-lactam antibiotic potentiated the antibacterial activity of the other against this microorganism as either
a mixture or as a reacted ion pair. Additivity was also found for P. aeruginosa 27853 when a
stoichiometric equivalent mixture of chlorhexidine diacetate and sodium antibiotic were used. Yet, the
greatest instance of synergy was found when chlorhexidine di-oxacillin was used; whereas, interactions
shifted towards additivity as less hydrophobic and smaller antibiotics were used in the antimicrobial
mixture against P. aeruginosa 27853.
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A similar response was found upon multi-drug-resistant Gram-negative bacteria treated with
chlorhexidine di-ampicillin GUMBOS (Figure 2a). In 92% of the isolates tested, reduced MICs were
needed to inhibit multi-drug-resistant Gram-negative bacteria growth. Approximately 15 and 37 μM of
chlorhexidine di-ampicillin and its stoichiometric equivalent mixture of chlorhexidine diacetate and
sodium ampicillin, respectively, were needed to inhibit multi-drug-resistant Gram-negative bacteria.
This approximate two-fold difference in MIC values between the unreacted mixture and chlorhexidine
di-ampicillin was apparent against all multi-drug-resistant Gram-negative bacteria, except S. marcescens.
Most of the unreacted mixtures of chlorhexidine diacetate and sodium ampicillin were additive, although
there were few instances of antagonism among isolates (Figure 2b). Synergy was determined for
chlorhexidine di-ampicillin GUMBOS among 69% of the multi-drug resistant Gram-negative bacteria
isolates (Figure 2b). Figure 3 summarizes the interaction indices for GUMBOS against Gram-positive
bacteria and GNB revealing that synergy was evident for most of the microorganisms tested.

Figure 2. (a) MICs and (b) FICIs of chlorhexidine di-ampicillin (CHX Amp) GUMBOS
and the unreacted stoichiometric equivalent (1 CHX: 2 Amp mixture) against 15
multi-drug-resistant Gram-negative bacteria.
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Figure 3. FICIs of β-lactam-based chlorhexidine GUMBOS determined on 17 clinical
isolates of Gram-negative bacteria of varying antibiotic resistance.
2.4. Cytotoxicity and Therapeutic Indices of Chlorhexidine and β-Lactam Antibiotics in Combination
and as GUMBOS
Adjunctive wound treatment options are successful in removing the source of infection, but can
exacerbate damage to the surrounding tissues and interrupt the natural wound healing process if too
potent and consequently toxic. This issue is a critical area in which many effective antimicrobial drug
therapies fail [3,38,39]. It is known that β-lactam antibiotics are highly nontoxic (>500 µM); however,
issues of toxicity caused by systemic administration of chlorhexidine diacetate limit its therapeutic
application. In order for GUMBOS to be a feasible alternative to combination drug treatment strategies,
concerns for chlorhexidine toxicity, despite its approved topical use, needs to be minimized. Thus,
cytotoxicity and therapeutic indices of the GUMBOS and their stoichiometric mixtures upon mammalian
cells critical to superficial and chronic wounds were evaluated to realize the utility of GUMBOS in
wound treatment regimens initiated by multi-drug-resistant Gram-negative bacteria (Table 6).
Fibroblasts were chosen to simulate the cell type responsible for healing superficial wounds or
abrasions. Chlorhexidine diacetate is a common antiseptic used to manage superficial abrasions. As
expected, chlorhexidine diacetate and the β-lactam antibiotics were equally nontoxic to fibroblast cells.
Likewise, the stoichiometric mixture and GUMBOS were equally nontoxic to the fibroblast cells as the
parent drugs. These results suggest that GUMBOS can also be used as topical disinfectants without
interfering with the proliferative phase of the wound healing process that occurs during superficial or
chronic wound recovery. Therapeutic indices for each chlorhexidine GUMBOS and fibroblasts cells
decreased in this order: drug-susceptible Gram-negative bacteria > drug-susceptible Gram-positive
bacteria = MRSA > multi-drug resistant Gram-negative bacteria (Figure 4). Variation among the
therapeutic indices determined for the GUMBOS were statistically insignificant (p < 0.05).
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Table 6. Acute cytotoxicity (LD50, µM) of β-lactam-based chlorhexidine GUMBOS.
Antibacterial Agents a
CHX Ac
1 CHX:2 Amp
CHX Amp
1 CHX:1 Carb
CHX Carb
1 CHX:2 Ceph
CHX Ceph
1 CHX:2 Oxa
CHX Oxa

Cervical
43 ±3
76 ±4
149 ±8
58 ±3
44 ±2
65 ±6
79 ±2
92 ±3
139 ±8

Fibroblasts
47 ±2
43 ±2
48 ±3
51 ±4
48 ±7
52 ±6
52 ±5
44 ±4
48 ±4

Endothelial
80 ±3
67 ±11
109 ±6
59 ±4
73 ±10
103 ±14
150 ±13
92 ±7
97 ±16

a

1 CHX: 2 Amp: 1 mole chlorhexidine diacetate: 2 moles sodium ampicillin; CHX Amp: chlorhexidine
di-ampicillin; 1 CHX: 1 Carb: 1 mole chlorhexidine diacetate: 1 mole disodium carbenicillin; CHX Carb:
chlorhexidine carbenicillin; 1 CHX: 2 Ceph: 1 mole chlorhexidine diacetate: 2 moles sodium cephalothin; CHX
Ceph: chlorhexidine di-cephalothin; 1 CHX: 2 Oxa: 1 mole chlorhexidine diacetate: 2 moles sodium oxacillin;
CHX Oxa: chlorhexidine di-oxacillin.

Chronic wounds, like diabetic foot ulcers, severe burns or non-healing surgical wounds, often provide
an optimal climate for opportunistic drug-resistant infections to persist and result in blood sepsis [3,38].
Since the vascularity of chronic wounds is limited, it is difficult to administer effective systemic therapy
for these ailments. Moreover, potent antimicrobials may aggravate the thin endothelial lining and
interfere with the wound healing process during treatment. Therefore, in vitro cytotoxicity of GUMBOS
and the unreacted drug pair upon endothelial cells was evaluated to determine if GUMBOS were an
effective, nontoxic treatment for chronic wounds caused by multi-drug-resistant bacteria. Our findings
show that unreacted drug mixtures containing stoichiometric equivalents of chlorhexidine diacetate and
sodium antibiotic were more cytotoxic than the respective GUMBOS (Table 6). Overall, endothelial
cytotoxicity of the investigated GUMBOS and corresponding stoichiometric drug combinations, from
least to greatest, occurred in this order (by anion): cephalothin < ampicillin < oxacillin < carbenicillin.
In comparison to fibroblasts, nearly 2–3× greater concentrations of GUMBOS could be used to manage
chronic wounds. As the status of the wound progresses from chronic to superficial, however, the
concentration of GUMBOS would need to be reduced. Therapeutic indices for each chlorhexidine
GUMBOS with endothelial cells were the same as fibroblasts, and theoretical dosing options were at
least twice as flexible (Figure 4). Variations among therapeutic indices were statistically significant
(p < 0.05) and were reflected among each group of bacteria studied.
For a general approximation of systemic cytotoxicity and probable use in eradicating infections of
the cervix, cervical cells were used. It was found that cervical toxicity caused by GUMBOS increased
in this order (by anion): ampicillin < oxacillin < cephalothin ≤ carbenicillin. Chlorhexidine carbenicillin
showed indifferent toxicity to chlorhexidine diacetate, while the other GUMBOS and mixtures were less
toxic to cervical cells (Table 6). In comparison to chlorhexidine diacetate, therapeutic indices for
GUMBOS improved as much as five-times as compared to chlorhexidine diacetate (Figure 4). Broad
therapeutic indices were also found for GUMBOS and cervical cells in an order similar to the other cell
lines. The greatest range of therapy was found for chlorhexidine di-ampicillin and chlorhexidine
di-oxacillin. Variation among therapeutic indices was statistically significant (p < 0.05).
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Figure 4. Theoretical therapeutic indices of β-lactam-based chlorhexidine GUMBOS determined from (a) drug-susceptible Gram-negative
bacteria, (b) multi-drug-resistant Gram-negative bacteria, (c) drug-susceptible Gram-positive bacteria and (d) MRSA, against cervical,
fibroblasts and endothelial cell lines.
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2.5. Limitations
These results also demonstrate that this approach may have its limitations, as well. There is a
possibility that each drug combination may not show any difference in activity or toxicity as compared
to the precursor drug or its use in an unreacted mixture. An example of this is found when comparing
the structurally similar chlorhexidine carbenicillin to chlorhexidine di-ampicillin. Throughout this study,
we have observed superior performance of chlorhexidine di-ampicillin to that of chlorhexidine
carbenicillin. In fact, chlorhexidine carbenicillin typically was equally cytotoxic as chlorhexidine
diacetate. More specifically, chlorhexidine carbenicillin was 2–4× more cytotoxic than chlorhexidine
di-ampicillin. This is attributable to the difference in structure and resultant stoichiometry between the
cation and anion constituents. Carbenicillin and ampicillin are structurally similar with the exception of
the carboxylate or primary amine, respectively located on the C-8 position of the antibiotic. This
secondary carboxylate on carbenicillin allows it to be di-anionic as compared to the mono-anionic charge
of ampicillin. After reacting the chlorhexidine with either antibiotic, a 1:1 chlorhexidine-carbenicillin
stoichiometry and 1:2 chlorhexidine-ampicillin stoichiometry are achieved. Although experiments are
still underway to understand the role of stoichiometry in the antibacterial and cytotoxic properties of
GUMBOS, we believe that the structural configuration of the 1:2 stoichiometric GUMBOS as compared
to the 1:1 stoichiometric GUMBOS affects the properties reported herein. This is especially since all 1:2
chlorhexidine-β-lactam antibiotic GUMBOS were continuously superior to chlorhexidine carbenicillin.
3. Experimental Section
3.1. Antibacterial Agents
Chlorhexidine diacetate, sodium ampicillin, sodium oxacillin, sodium cephalothin, disodium
carbenicillin, methanol, dimethylsulfoxide, 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium
bromide and Corning 3695 flat-well 96-well plates were purchased from Sigma Aldrich (St. Louis, MO,
USA) and used without further purification. Cation-adjusted Mueller–Hinton broth and the BD Gentest
Pre-coated PAMPA Plate System were obtained from BD Biosciences (Franklin Lakes, NJ, USA).
3.2. Synthesis of β-Lactam-Based Chlorhexidine GUMBOS
The synthesis and physical characterization of four β-lactam-based chlorhexidine GUMBOS, namely
chlorhexidine di-ampicillin, chlorhexidine carbenicillin, chlorhexidine di-cephalothin and chlorhexidine
di-oxacillin, were performed using methods previously reported by Cole et al. (2013) [24], but with
slight modification. Briefly, stoichiometric amounts of chlorhexidine diacetate and β-lactam antibiotic,
with the latter in slight excess, was stirred for 48 h at room temperature in a butanol:water (1:1) mixture
to ensure the complete formation of the β-lactam-based chlorhexidine GUMBOS. After removing
butanol from the GUMBOS products, they were purified by washing several times with cold deionized
water and dried overnight with a high vacuum. The structures of chlorhexidine di-ampicillin,
chlorhexidine carbenicillin, chlorhexidine di-oxacillin and chlorhexidine di-cephalothin (Figure 1) were
mainly confirmed by NMR, mass spectrometry and elemental analysis, among other spectroscopic data.

Molecules 2015, 20

6481

Chlorhexidine di-ampicillin. Off-White Solid, yield 98%, Water solubility: 126 μg/mL. Solubility
product constant (Ksp): 4.63 × 10−12 M3. 1H-NMR (400 Hz, DMSO-d6) δ 8.58–8.36 (m, 2 H) 7.21–7.50
(m, 18 H), 5.08 (d, J = 2.74 Hz, 2 H), 4.96 (s, 4 H), 3.69 (d, J = 3.13 Hz, 2 H), 3.26 (s, 2 H), 3.07 (dt,
J = 7.04, 6.65 Hz, 4 H), 1.85 (s, 4 H), 1.57 (s, 6 H), 1.49 (s, 4 H), 1.46 (quin, 4 H), 1.44 (s, 4 H), 1.27
(quin, 4 H), 1.17 (s, 6 H), 1.15 (s, 2 H). 13C-NMR (101 MHz, DMSO) δ 180.88, 72.88, 172.36, 166.94,
166.76, 139.07, 128.24, 127.01–128.43, 121.90, 76.07, 68.38, 60.80, 60.01, 58.64, 27.38, 26.76, 25.97.
Anal. calcd. for C54H68Cl2N16O8S2: C, 53.86; H, 5.69; Cl, 5.89; N, 18.61; O, 10.63; S, 5.33. Found: C,
53.22; H, 5.81; Cl, 5.56; N, 18.37; S, 5.16. HRMS (ESI) m/z calcd. for C54H68Cl2N16O8S2, [M+H+],
1203.4424; found, 1203.4136.
Chlorhexidine carbenicillin. Colorless Solid, yield 93%, Water solubility: 55 μg/mL. Ksp: 3.53 × 10−9 M2.
1
H-NMR (400 Hz, DMSO-d6) δ 0.69–0.76 (m, 1 H) 0.96 (s, 1 H) 1.06 (s, 2 H) 1.15 (s, 4 H) 1.34 (s, 4 H)
1.40–1.54 (m, 5 H) 1.61 (s, 2 H) 2.96 (s, 4 H) 3.07 (s, 1 H) 3.16–3.34 (m, 3 H) 3.43 (d, J = 5.14 Hz,
1 H) 3.47–3.51 (m, 1 H) 3.52–3.56 (m, 1 H) 3.92–1303.99 (m, 1 H) 4.18–4.27 (m, 1 H) 4.82 (s, 1 H)
6.96–7.20 (m, 9 H) 7.28 (s, 3 H) 7.36–7.68 (m, 2 H) 8.24–8.35 (m, 1 H). 13C-NMR (101 MHz, DMSO)
δ 128.71, 122.65, 108.20, 40.40, 40.19, 26.42. Anal. calcd. for C39H48Cl2N12O6S: C, 53.00; H, 5.47; Cl,
8.02; N, 19.02; O, 10.86; S, 3.63. Found: C, 51.12; H, 5.68; Cl, 7.74; N, 18.34; S, 3.50. HRMS (ESI)
m/z calcd. for C39H48Cl2N12O6S, [M+], 883.8462; found, 883.8457.
Chlorhexidine di-cephalothin. Orange Solid, yield 83%, Water solubility: 79 μg/mL. Ksp:
1.89 × 10−11 M3. 1H-NMR (400 MHz, DMSO-d6) δ1.27 (s, 5 H) 1.45 (s, 6 H) 1.79 (d, J = 3.42 Hz, 1 H)
2.01 (s, 6 H) 3.07 (s, 5 H) 3.17 (s, 3 H) 3.27(d, J = 17.61 Hz, 3 H) 3.33 (s, 4 H) 3.50 (d, J = 17.36 Hz,
3 H) 3.77 (d, J = 2.93 Hz, 4 H) 4.79 (d, J = 11.98 Hz, 2 H) 5.00 (d, J = 4.65 Hz, 3 H) 5.03(s, 1 H) 5.53
(dd, J = 8.31, 4.89 Hz, 2 H) 6.89–6.98 (m, 5 H) 7.29 (d, J = 8.80 Hz, 6 H) 7.33–7.38 (m, 2 H) 7.44 (d,
J = 8.31 Hz, 13 H) 9.03 (d, J = 8.31 Hz, 2 H).13C-NMR (101 MHz, DMSO) δ 170.97, 170.41, 165.77,
163.59, 137.47, 134.44, 128.71, 127.04, 126.69, 125.39, 122.47, 113.60, 64.77, 59.12, 57.67, 40.63,
40.42, 36.23, 26.42, 25.64, 21.17. Anal. calcd. for C54H62Cl2N14O12S4: C, 49.96; H, 4.81; Cl, 5.46; N,
15.10; O, 14.79; S, 9.88. Found: C, 48.61; H, 4.99; Cl, 5.31; N, 14.70; S, 9.61. HRMS (ESI) m/z calcd.
for C54H62Cl2N14O12S4, [M+], 1298.3227; found, 1298.3199.
Chlorhexidine di-oxacillin. Colorless Solid, yield 85%, Water solubility: 166 μg/mL. Ksp: 8.38 ×10−12 M3.
1
H-NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 9.0 Hz, 4H), 7.90–7.85 (m, 2H), 7.76 (d, J = 7.6 Hz, 4H),
7.71–7.64 (s, 1H), 7.60–7.52 (m, 2 H). 7.52–7.43 (m, 15H), 7.38 (t, J = 7.4 Hz, 2H), 7.28 (d, J = 8.4Hz),
4.96 (d, J = 8.0 Hz, 2 H), 4.61 (t, J = 8.4 Hz, 2H), 3.67 (s, 8 H), 3.40 ( s., 1 H), 3.27 (s, 2H), 3.05 (s, 4
H), 1.55 (s, 6H), 1.43 (m, 4H), 1.25(m, 4H), 1311.19 (s, 6H). 13C-NMR (101 MHz, DMSO) δ 173.07,
1708.51, 169.46, 161.59, 159.98, 138.94, 129.85, 128.77, 128.22, 127.87, 121.84, 112.43, 75.22, 65.84,
59.67, 57.77, 52.01, 27.83, 26.02, 11.81. Anal. calcd. for C60H68C l2N16O10S2: C, 55.08; H, 5.24; Cl,
5.42; N, 17.13; O, 12.23; S, 4.90. Found: C, 53.61; H, 5.40; Cl, 5.27; N, 16.67; S, 4.77. HRMS (ESI)
m/z calcd. for C60H68Cl2N16O10S2, [M+], 1308.3191; found, 1308.30.
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3.3. Bacterial Strains
Twenty-five clinical isolates were obtained from critically ill patients sent to Professor Jeffrey A.
Hobden, Louisiana State University Health Science Center, LA, for drug-resistance screening and
antibiotic susceptibility.
3.4. Media
Cation-adjusted Mueller–Hinton broth (MHB, Becton Dickinson and Company, Franklin Lakes,
NJ, USA) with 1% DMSO was used to determine minimum inhibitory concentrations (MICs) and
synergy experiments.
3.5. Minimum Inhibitory Concentrations and Synergy Experiments
MICs of GUMBOS, parent ions and unreacted mixtures were determined by standard broth dilution
in 96-well microtiter plates. GUMBOS, parent ions and the unreacted mixtures (500 mM) were dissolved
in DMSO to prepare a stock solution of known concentration. Then, 1 µL of each stock was injected
into wells containing 100 µL MHB to a starting concentration of 5000 µM (1% DMSO). The compounds
were serially diluted (1:1) to yield a concentration range between 0.1 and 2500 μM at a 100-μL volume.
Equal volume (100 μL) of starting inocula matching a 0.5 McFarland standard were added to each well
and incubated at 37 °C for 24 h. Unreacted mixtures consisted of stoichiometric equivalents of
chlorhexidine and sodium antibiotic to the GUMBOS (i.e., 1 mole of chlorhexidine diacetate and 2 moles
of ampicillin, cephalothin and oxacillin or 1 mole of carbenicillin). Turbidity was used as an initial
indication of microbial growth, and if present, the corresponding concentration of antibacterial agent
was considered ineffective. Absorbance was recorded 30 minutes after injecting 20 µL MTT (1 mg/mL)
and 80 μL lysing solution (30% sodium dodecyl sulfate and 10% DMSO) in to each well to determine
percent inhibition values for each concentration tested per organism. To eliminate differences in
concentrations that arise from molecular weight differences of GUMBOS, precursor ions and their
unreacted mixtures, molar concentrations were used to compare the antibacterial activities and for
statistical analysis. This would result in micromolar MIC values that are not of conventional dilution
concentrations. Antibacterial activity was analyzed by analysis of variance (ANOVA) with comparisons
of means to check statistical significance using SAS 9.2 2 (SAS Institute Inc., Cary, NC, USA), p < 0.05.
3.6. Interaction Indices and Synergy Testing
Loewe’s additivity model was used to assess the fractional interaction index (FICI) between ion pairs
for the reacted GUMBOS and unreacted ion mixture (chlorhexidine diacetate + sodium antibiotic) [24].
Minimum inhibitory concentrations acquired for stoichiometric mixtures and GUMBOS were used to
tabulate FICI values. The FICI values were interpreted as follows: (1) FICI ≤ 0.5, synergy;
(2) 0.5 ≤ FICI ≤ 3, additive or neutral; and (3) FICI >3, antagonism. Equations (1)–(3) were used to
calculate FICI values between the ions in the GUMBOS or the unreacted, stoichiometric mixture of ions.
Chlorhexidine di-ampicillin, chlorhexidine di-cephalothin and chlorhexidine di-oxacillin were
determined with Equation (2) to calculate FICI values; whereas, chlorhexidine carbenicillin with
Equation (3).
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FICIGUMBOS 

FICIGUMBOS 

[CHX ]COMBO [   lactam]COMBO

[CHXAc]100%
[   lactam]100%

0.33  [CHXAmp2 ]
[CHX ][ Ac2 ]100%
0.50  [CHXCarb ]
[CHX ][ Ac2 ]100%

(1)



0.66  [CHXAmp2 ]
[ Na ][ Amp]100%

(2)



0.50  [CHXCarb ]
[ Na 2 ][Carb ]100%

(3)

3.7. Dissolution Profile Measurement
The dissolution rates for β-lactam-based chlorhexidine GUMBOS were measured using a method
similar to Lengsfeld et al. (2002) [32]. Here, 20 mg GUMBOS were stirred 50 mL of deionized water.
Over time, 1-mL aliquots were collected and filtered through a 0.1-µm syringe filter and analyzed
spectrophotometrically at 260 nm in triplicate until the absorbance values approached a plateau.
3.8. In Vivo Prediction of Intestinal Permeability Coefficients and Absorption
Intestinal permeability was approximated using a protocol outlined in the BD Gentest Pre-coated
PAMPA Plate System Assay (BD Biosciences, Bedford, MA, USA). Membrane permeability was
calculated using formulas provided in the assay, and resultant predictive intestinal absorption values
were determined using a log permeability coefficient ≤−6 threshold that estimates ≥75% intestinal
absorption. Predictive intestinal absorption was analyzed by analysis of variance (ANOVA) with
comparisons of means to check statistical significance using SAS 9.2 2 (SAS Institute Inc., Cary, NC,
USA), p < 0.05.
3.9. Mammalian Cytotoxicity
In vitro experiments were performed using fibroblasts (NIH/3T3), endothelial (EOMA) and cervical
(HeLa) cell lines (ATCC, Manassas, VA, USA) by Karen McDonough of the Veterinary Science
Department at Louisiana State University using conventional cell viability methods. Cytotoxicities of
chlorhexidine-based salts and their stoichiometric mixtures were determined using the MTT assay kit
(Promega Corporation, Madison, WI, USA). Test compounds up to 500 µM were serially diluted directly
into cell culture media and transferred to seeded cells (×109). Each concentration was performed in
triplicate. Cells were incubated for 24 h at 37 °C, in 5% CO2 atmosphere. At the end of the incubation
period, cell viability was quantified at 570 nm in a microplate spectrophotometer (Benchmark plus
Bio-Rad Laboratories, Hercules, CA, USA). Cell viability as a percentage was determined by computing
the ratio between absorbance of the treated cells and the absorbance of untreated (control) cells taken as
100%. Reported values are the lethal concentrations able to kill 50% of the population of viable cells
(LD50). Therapeutic indices were calculated by dividing the mean MIC value per group of
microorganisms (i.e., drug susceptible Gram-positive bacteria, MRSA, drug susceptible GNB and
multi-drug-resistant Gram-negative bacteria) into the LD50 for each cell type. Cytotoxicity results were
analyzed by analysis of variance (ANOVA) with comparisons of means to check statistical significance
using SAS 9.2 2 (SAS Institute Inc., Cary, NC, USA), p < 0.05.
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4. Conclusions
The use of reacted ion pairs (GUMBOS) composed of previously approved drugs and outmoded
antibiotics shows promise as an alternative combinatorial drug strategy for treating wound infections
caused by drug-resistant bacteria. GUMBOS formed from β-lactam antibiotics and chlorhexidine
diacetate were found to: (1) extend the spectra of antibacterial activity with profound antibacterial
activity; and (2) lower the concentration required to inhibit the growth of multi-drug-resistant bacteria
better than the unreacted, stoichiometric equivalent of precursor ions. Even more so, GUMBOS were
less toxic to invasive cell types commonly found in superficial and chronic wounds. Overall, this
approach may offer an alternative approach to contain ion-pairs and effectively execute the principles of
combination drug therapy. Future studies include investigating mechanisms of action, identifying
GUMBOS potential in mitigating other diseases for which combination drug therapy is commonly
applied and evaluating drug pharmacokinetic behavior using in vivo animal models.
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